fashion -WSS

fashion

author：focus 2025-10-02 07:45:07 - browse：2

Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the longtime and polarizing director Alex Denner would step down from its board, sending a signal to investors that the company’s fractious recent history might be coming to a close.

What Biogen didn’t disclose is that its nominee to replace Denner on the board, Susan Langer, is Denner’s live-in romantic partner and the mother of his child, born in November, according to court records obtained by STAT. Denner is in the middle of a protracted divorce from his wife of nearly 25 years, with whom he has two teenage sons — a bitter legal fight in which his extramarital relationship with Langer is a contentious issue, according to the records.

Biogen spokesperson Jack Cox said the company knew about the relationship between Denner and Langer. He also said that Denner recommended Langer to Biogen’s board — he said he incorrectly stated at first that Denner nominated her — but declined to comment on the company’s vetting process and whether it planned to disclose the relationship to shareholders before they vote on Langer’s candidacy later this month. Biogen also omitted mention of the relationship from Langer’s biography in a Securities and Exchange Commission filing Tuesday morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Amylyx ALS drug fails large clinical trial

focus

explore

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

CVS is willing to dump 10% of its Medicare Advantage members

Free medical tuition alone isn't enough to close gaps in primary care

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Oak Street deal isn't the answer to health care's woes

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Wikipedia

fashion

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

NEJM study link tiny plastics in blood vessels to heart problems

Medicare details structure of new drug price negotiation program

First medicine developed to treat MASH expected to be approved soon

How one medical school became remarkably diverse

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

BioMarin wins approval for gene therapy to treat hemophilia A

HHS suspends federal funding for EcoHealth Alliance

Moonlake's readout produced a cash windfall. Risks remain

STAT reporters are Pulitzer Prize finalists for investigative reporting

hotspot

The White House hikes tariffs on plastic syringes made in China

Boston hospital trains restaurant workers on naloxone for overdoses

Obesity drug from Roche shows promise in early study

Amylyx ALS drug failure raises questions and concerns

Air quality improving but still lags in Black, Hispanic communities

Novo Nordisk testing Wegovy against alcohol

focus

focus

explore

leisure time